Genmab A/S to present at the dbVIC - Deutsche Bank ADR Virtual Investor Conference on March 22, 2018

Wednesday, March 21, 2018 General News
Email Print This Page Comment bookmark
Font : A-A+

Company invites individual and institutional investors, as well as advisors, to attend interactive, real-time virtual event

COPENHAGEN,

Denmark, March 21, 2018 /PRNewswire/ -- Genmab A/S (CPH: GEN.CO, OTC Pink: GMXAY), focused on the creation and development of differentiated antibody therapeutics for the treatment of cancer, today announced that
Genmab's Senior Vice President, IR & Communications, Rachel Curtis Gravesen, will present at the dbVIC - Deutsche Bank American Depositary Receipt (ADR) Virtual Investor Conference on March 22, 2018.  This virtual investor conference is aimed exclusively at introducing global companies with ADR programs to investors.

DATE: March 22nd, 2018TIME:    12.30pm ETLINK:    https://tinyurl.com/dbvic03prepr

This will be a live, interactive online event where investors are invited to ask international companies their questions in real-time and to download a company's information in their "virtual trade booth" in the Exhibits section. If attendees are not able to join the event live on the day of the conference, an on-demand archive will be available for 90 days.

Participation is free of charge.

It is recommended that investors pre-register to save time and receive event updates.

About Genmab A/SGenmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers, and solid tumors. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis.  Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies. The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies. For more information visit www.genmab.com.

Cision View original content:http://www.prnewswire.com/news-releases/genmab-as-to-present-at-the-dbvic---deutsche-bank-adr-virtual-investor-conference-on-march-22-2018-300617571.html

SOURCE Genmab A/S

Advertisement


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store